

DLL4 & VEGFA Research Grade Navicixizumab

Catalog No.	DHJ65303A DHJ65303B	Quantity:	100 µg 1.0 mg
Alternate Names:	Bispecific, OMP-305B83, CAS: 1638338-43-8		
Description:	Research Grade Navicixizumab is a bispecific chimeric humanized monoclonal antibody which targets human Delta-like protein 4 and Vascular endothelial growth factor A.		
UniProt ID (target):	Q9NR61 & P15692		
Target:	Human Delta-like protein 4 and VEGF-A		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO		
Isotype:	Chimeric Human IgG2 kappa		
Formulation:	0.01M PBS buffer, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
INN:	Navicixizumab		
Applications:	Functional studies		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.